A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Atherogenic dyslipidemia includes patients who have coronary heart disease (CHD) or CHD risk
equivalents, whose TG level is not adequately controlled after statin monotherapy. According
to the published ESC/EAS consensus, fibrate is suggested to be added to this type of patient
who has insufficient improvement. The purpose of the study is to evaluate the efficacy on
lipid control and the safety of adding fenofibrate in patients on a background of statin
treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Abbott
Collaborator:
Rundo International Pharmaceutical Research & Development Co.,Ltd.